Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisition could bolster the stent portfolio of Johnson & Johnson's Cordis unit, helping it retain top-tier market share as a flurry of new competitors joins the market. Conor expects to submit an application to FDA next year for its paclitaxel-eluting, cobalt-chromium coronary stent with a bioabsorbable polymer coating, which has yet to show any cases of late stent thrombosis in clincial trials.

You may also be interested in...



Congress Urged To Address Expanded OMB Role In Regulations, Guidances

The government watchdog group OMB Watch is urging Congress to take action against an executive order that increases the administration's influence over regulations and guidance documents issued by FDA and other agencies

Nuvasive Grows Bone Graft Basket For Spinal Fusion

The San Diego firm is diversifying its spinal fusion offerings with a $16 million purchase of the Formagraft synthetic bone graft product line.

Bioject Could Fold In June Without Additional Financing

Needle-free drug-delivery system manufacturer needs to generate $3 mil. in a financing round in order to continue operations past May 31.

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel